NCT07431554 Effect of Acute Hypoxia on RIght VEntRicular Function in HAPE.
| NCT ID | NCT07431554 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mona Lichtblau |
| Condition | Altitude Hypoxia |
| Study Type | INTERVENTIONAL |
| Enrollment | 18 participants |
| Start Date | 2026-03-17 |
| Primary Completion | 2030-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 18 participants in total. It began in 2026-03-17 with a primary completion date of 2030-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
More and more people are engaging in sports in the mountains, including individuals with heart or lung diseases. At the same time, such diseases are becoming more common in Switzerland. At high altitude, less oxygen is available, which places stress on the body-particularly on the heart, which has to pump blood through the lungs. How the heart, especially the right ventricle, in people with past HAPE responds to this stress is still not well understood. Therefore, this study investigates how the heart responds to simulated altitudes of 2,500 m and 4,000 m, both at rest and during light physical activity in patients with past HAPE. The primary objective is to assess how right ventricular function changes under conditions of reduced oxygen availability. In addition, vital signs, changes in blood gases, oxygen levels in blood and tissue and shortness of breath are assessed. The "altitude" is simulated using a special gas mixture that participants inhale. Participants undergo three altitude conditions (490, 2,500, and 4,000 m above sea level). The order of the altitude conditions is assigned at random. The aim is to better understand how the right ventricle and other parameters respond to low-oxygen conditions and how affected patients can be better supported in the future.
Eligibility Criteria
Inclusion Criteria: * Signed informed consent * Diagnosed or suspicion of past HAPE * 18-80 years (age group young: 18-39.99 years / age group older: 40-80 years) * All sex and genders * Living \<800m and without altitude exposure \> 2500 m and \> 24h within the last three weeks Exclusion Criteria: * \<18, \>80 years old * Any other diagnosed cardiopulmonary condition * Other clinically significant severe concomitant disease states (e.g. renal, hepatic dysfunction, etc.) * Inability to follow the procedures of the study due to language problems, psychological neurological disorders or orthopaedic disorders * Participants permanently living \>800m and altitude exposure \> 2500 m and \>24h within the last three weeks * Pregnancy: Participants will be asked if pregnant or not, no screening for undetected pregnancy * Lactating women * Participation in other study with active treatment
Contact & Investigator
Mona Lichtblau
PRINCIPAL INVESTIGATOR
University of Zurich
Frequently Asked Questions
Who can join the NCT07431554 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Altitude Hypoxia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07431554 currently recruiting?
Yes, NCT07431554 is actively recruiting participants. Contact the research team at mona.lichtblau@usz.ch for enrollment information.
Where is the NCT07431554 trial being conducted?
This trial is being conducted at Zurich, Switzerland.
Who is sponsoring the NCT07431554 clinical trial?
NCT07431554 is sponsored by Mona Lichtblau. The principal investigator is Mona Lichtblau at University of Zurich. The trial plans to enroll 18 participants.